R&D News | pharmaphorum

News

Merdad Parsey will leave Gilead next year

Gilead Sciences' chief medical officer, Merdad Parsey, will leave the company in early 2025, becoming the latest in a series of high-profile departures involving senior R&D figures at t

News

Trial sets up wider use of Bayer's Nubeqa in prostate cancer

Bayer has the result it was hoping for in the phase 3 ARANOTE trial of Nubeqa in metastatic, hormone-sensitive prostate cancer (mHSPC), a key part of its plan to build the drug into a €3 bi

News

Roche reveals first data with Carmot-sourced oral GLP-1 drug

Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of its $3.1 billion takeover of Carmot Therapeutics as it tries to catch up with the leaders in the

News

Vertex, Orum partner on safer pre-treatment for gene meds

Vertex Pharma has teamed up with Orum Therapeutics to develop a conditioning regimen, used to prepare patients to receive gene-editing medicines, that it hopes will offer a more tolerable a

News

GLP-1 bonanza spurs big investment at CDMO CordenPharma

CordenPharma has launched a €900 million ($981 million) investment programme to prepare for an expected surge in demand for peptide production capacity – driven by GLP-1 receptor agonists.

News

Dr Fred Aslan, Artiva's president and chief executive

Artiva announces terms for its second IPO attempt

After abandoning its first initial public offering (IPO) filed in 2021, natural killer (NK) cell therapy specialist Artiva Biotherapeutics is having another go.

Merdad Parsey will leave Gilead next year

Trial sets up wider use of Bayer's Nubeqa in prostate cancer

Roche reveals first data with Carmot-sourced oral GLP-1 drug

Vertex, Orum partner on safer pre-treatment for gene meds

GLP-1 bonanza spurs big investment at CDMO CordenPharma

Artiva announces terms for its second IPO attempt

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks